Zurcher Kantonalbank Zurich Cantonalbank Grows Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Zurcher Kantonalbank Zurich Cantonalbank raised its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 2.9% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 438,879 shares of the company’s stock after buying an additional 12,338 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Teva Pharmaceutical Industries were worth $7,132,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Lingotto Investment Management LLP increased its stake in shares of Teva Pharmaceutical Industries by 1.8% during the fourth quarter. Lingotto Investment Management LLP now owns 34,457,656 shares of the company’s stock worth $359,738,000 after purchasing an additional 607,800 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd increased its stake in shares of Teva Pharmaceutical Industries by 7.1% during the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 32,804,131 shares of the company’s stock worth $342,788,000 after purchasing an additional 2,188,212 shares in the last quarter. Sound Shore Management Inc. CT increased its stake in shares of Teva Pharmaceutical Industries by 12.6% during the fourth quarter. Sound Shore Management Inc. CT now owns 8,919,234 shares of the company’s stock worth $93,117,000 after purchasing an additional 998,522 shares in the last quarter. Maple Rock Capital Partners Inc. increased its stake in shares of Teva Pharmaceutical Industries by 68.3% during the first quarter. Maple Rock Capital Partners Inc. now owns 4,363,401 shares of the company’s stock worth $61,568,000 after purchasing an additional 1,770,000 shares in the last quarter. Finally, Iron Triangle Partners LP increased its stake in shares of Teva Pharmaceutical Industries by 113.1% during the first quarter. Iron Triangle Partners LP now owns 2,769,864 shares of the company’s stock worth $39,083,000 after purchasing an additional 1,469,864 shares in the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Insider Transactions at Teva Pharmaceutical Industries

In other news, Director Roberto Mignone sold 519,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 18th. The shares were sold at an average price of $17.03, for a total value of $8,838,570.00. Following the transaction, the director now directly owns 981,000 shares in the company, valued at approximately $16,706,430. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, Director Roberto Mignone sold 519,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 18th. The shares were sold at an average price of $17.03, for a total transaction of $8,838,570.00. Following the sale, the director now directly owns 981,000 shares of the company’s stock, valued at approximately $16,706,430. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Eric A. Hughes sold 24,537 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $17.25, for a total transaction of $423,263.25. Following the sale, the insider now directly owns 45,060 shares in the company, valued at $777,285. The disclosure for this sale can be found here. Company insiders own 0.55% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently commented on TEVA shares. Barclays boosted their target price on shares of Teva Pharmaceutical Industries from $21.00 to $22.00 and gave the stock an “overweight” rating in a research note on Thursday, August 1st. Jefferies Financial Group boosted their price target on shares of Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the stock a “buy” rating in a research report on Thursday, June 27th. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 3rd. Bank of America boosted their price target on shares of Teva Pharmaceutical Industries from $18.00 to $21.00 and gave the stock a “buy” rating in a research report on Thursday, May 30th. Finally, Piper Sandler restated an “overweight” rating and set a $20.00 price target (up from $19.00) on shares of Teva Pharmaceutical Industries in a research report on Monday, May 13th. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Teva Pharmaceutical Industries presently has a consensus rating of “Moderate Buy” and an average price target of $18.67.

Teva Pharmaceutical Industries Price Performance

NYSE:TEVA remained flat at $18.73 on Friday. 3,442,184 shares of the company’s stock traded hands, compared to its average volume of 10,050,684. The company has a debt-to-equity ratio of 2.52, a quick ratio of 0.59 and a current ratio of 0.89. The firm has a market capitalization of $21.22 billion, a PE ratio of -45.68, a price-to-earnings-growth ratio of 1.28 and a beta of 0.90. The stock has a fifty day moving average price of $17.16 and a two-hundred day moving average price of $15.51. Teva Pharmaceutical Industries Limited has a 12 month low of $8.06 and a 12 month high of $18.89.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Wednesday, July 31st. The company reported $0.58 EPS for the quarter, topping the consensus estimate of $0.55 by $0.03. Teva Pharmaceutical Industries had a negative net margin of 2.73% and a positive return on equity of 39.66%. The firm had revenue of $4.16 billion for the quarter, compared to analyst estimates of $3.99 billion. As a group, analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.35 earnings per share for the current year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.